title: Management of severe refractory thrombocytopenia in dengue hemorrhagic fever with intravenous anti-D immune globulin.
abstract: Dengue hemorrhagic fever (DHF) is a potentially lethal complication of dengue fever due to shock and/or bleeding. Bleeding in DHF is due to thrombocytopenia and/or coagulopathy. The authors present their experience of usage of intravenous anti-D in 5 children with DHF and severe refractory thrombocytopenia (<10,000/mm(3)). It was administered in a dose of 50 to 75 μg/kg. Mean platelet count was 6800/mm(3) before and 33,600, 44,600, and 79,000/mm(3) after intravenous anti-D administration at 24, 48, and 72 hours, respectively. Average drop in hemoglobin after administration of anti-D was 2.28 g/dL. Intravenous anti-D can possibly be a treatment option for refractory thrombocytopenia in DHF.
authors.affiliation: Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Center for Child Health, Sir Ganga Ram Hospital, Delhi, India.
authors.forename: Gaurav
authors.initials: G
authors.lastname: Kharya
authors.forename: Satya Prakash
authors.initials: SP
authors.lastname: Yadav
authors.forename: Satyendra
authors.initials: S
authors.lastname: Katewa
authors.forename: Anupam
authors.initials: A
authors.lastname: Sachdeva
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D012189:Retrospective Studies; D018029:Rho(D) Immune Globulin / Q000627:therapeutic use*; D019595:Severe Dengue / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000188:drug therapy*
chemical_list: D016756:Immunoglobulins, Intravenous; D018029:Rho(D) Immune Globulin